Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Department of Nephrology, Huai'an Second People' Hospital and The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, Jiangsu, China.
J Cell Physiol. 2019 Feb;234(2):1062-1070. doi: 10.1002/jcp.27324. Epub 2018 Sep 6.
Portal vein tumor thrombosis (PVTT) is one of the most common complications in hepatocellular carcinoma (HCC). HCC with PVTT usually indicates poor prognosis, which has a number of characteristics including a rapidly progressive disease course, worse liver function, complications connected with portal hypertension, and poorer tolerance to treatment. The exact mechanisms of PVTT remain unknown, even though some concerned signal transduction or molecular pathways have been identified. In western countries, sorafenib is the only recommended therapeutic strategy regardless of PVTT types. However, multiple treatment options including transhepatic arterial chemoembolization, hepatectomy, radiotherapy, and sorafenib available in the clinic. In this review, we enumerate and discuss therapeutics against patients with HCC having PVTT available in the clinic and put forward directions for future research.
门静脉癌栓（PVTT）是肝细胞癌（HCC）最常见的并发症之一。合并 PVTT 的 HCC 通常预示着预后不良，其具有一些特征，包括疾病进展迅速、肝功能更差、与门静脉高压相关的并发症以及对治疗的耐受性更差。尽管已经确定了一些相关的信号转导或分子途径，但 PVTT 的确切机制仍不清楚。在西方国家，索拉非尼是唯一推荐的治疗策略，无论 PVTT 类型如何。然而，临床上有多种治疗选择，包括经肝动脉化疗栓塞术、肝切除术、放疗和索拉非尼。在这篇综述中，我们列举并讨论了临床上针对合并 PVTT 的 HCC 患者的治疗方法，并为未来的研究提出了方向。
